40971-95-7

Usage

General Description

6-CHLORO-3-(TRIFLUOROMETHYL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE is a chemical compound with the molecular formula C6H3ClF3N5. It is a heterocyclic compound containing a triazolo and pyridazine ring system. This chemical has a chloro group and a trifluoromethyl group attached to the triazolo ring. It has potential applications in the field of pharmaceuticals and agrochemicals due to its unique structural features. Its specific properties and potential uses would need to be further studied and evaluated in a laboratory setting.

Upstream product

• 17284-97-8 3-Chloro-6-hydrazinopyridazine 
• 407-25-0 trifluoroacetic anhydride 
• 76-05-1 trifluoroacetic acid 
• 401-67-2 2,2-difluoroacetic anhydride 

Downstream Products

• 1262619-07-7 6-(4-(trifluoromethoxy)phenyl)-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine 
• 312617-36-0 6-(piperidin-1-yl)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine 
• 338748-56-4 6-(piperazin-1-yl)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine 
• 1166816-05-2 6-(4-phenylpiperidin-1-yl)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine 
• 334500-45-7 C₁₆H₁₅F₃N₆ 
• 296243-50-0 C₁₇H₁₇F₃N₆ 
• 1166810-43-0 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine 
• 1332388-82-5 5-(4-hydroxyphenyl)-6-thioxo-7-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-5,7-diazaspiro[3.4]octan-8-one 
• 1240300-07-5 2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)-phenoxy)ethylmethanesulfonate 
• 1240300-21-3 1-methyl-4-(2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]-pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-2-one 
• 1255339-42-4 4-methyl-1-(2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]-pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-2-one 
• 1240300-06-4 2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)-phenoxy)ethanol 
• 1166820-04-7 4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenol 

Relevant academic research and scientific papers

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine

We started with a medium throughput screen of heterocyclic compounds without basic amine groups to avoid hERG and β-blocker activity and identified [1,2,4]triazolo[4,3-a]pyridine as an early lead. Optimization of substituents for Late INa curre

ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES

Provided are compounds with the following structure: Formula (I), and methods of making and using same. The methods of using the compounds may be methods for treating or prophylaxis of a cryptosporidium infection.

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography

A combination of conventional organic synthesis, remotely monitored flow synthesis and bioassay platforms, were used for the evaluation of novel inhibitors targeting bromodomains outside the well-studied bromodomain and extra terminal (BET) family, here e

DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS

The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.

FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.